Compare DexCom, Inc. (DXCM) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Standard Lithium Ltd — how do they compare? DexCom, Inc. trades at $90.8 (market cap $33.79B), while Standard Lithium Ltd trades at $2.42 (market cap $604.50M). The key difference: DexCom, Inc. is far larger — about 55.9× Standard Lithium Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| DXCM | SLI | |
|---|---|---|
Market Cap | $33.79B | $604.50M |
Sector | Health | Basic Materials |
52-Week High | $89.53 | $5.65 |
52-Week Low | $54.84 | $1.93 |
Enterprise Value | $33.24B | $467.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
SLI trades at $2.41, down 4.74% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported a net loss of $48.40M in 2025, with negative ROE and ROA, but beat EPS estimates in two recent quarters. Positive news includes a $225M DOE grant and progress on its South West Arkansas lithium project, with institutional buying from Amundi (64.9% stake increase in Q1 2026 per SEC filing).
The outlook hinges on project execution, as SLI transitions to production with strong analyst support (100% buy ratings). Key risks include cash burn from negative operating cash flow and reliance on financing, but de-risking milestones and government backing offer upside if timelines are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
